This is a real setback.
Strengthening their product range further down the value chain makes a lot of sense.
The company's salt acquisitions are paying off big time thanks to the winter weather.
I think Engelhard is opening up to a friendly transaction.
The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit.
This move comes as a surprise, but BASF so far has an excellent track record in acquisitions that were always adding value to investors.
It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it.
If the final price comes in over $40 per share, we would consider this negative.
This is a good amendment of Bayer's cardiology and hematology portfolio.